Meclonazepam

What You Need to Know

Aegis is pleased to offer industry-leading testing options to allow providers the opportunity to more completely understand an individual’s drug use pattern, and facilitate more informed care and harm reduction measures. Novel Psychoactive Substances (NPS) are compounds designed to mimic common illicit or prescription drugs while evading regulation and routine testing methods. They are also known as “designer drugs” or “research chemicals.”

  • Meclonazepam is an emerging designer benzodiazepine that has appeared in the illicit drug supply as part of the growing novel
    psychoactive substance (NPS) market. 1-3 Aegis monitors exposure through testing for its metabolite, 7 aminomeclonazepam, supporting detection of this evolving drug trend.
  • Meclonazepam detection at Aegis had nearly ceased at the end of 2025. The drug was again detected in June 2026, and frequency of detections has increased month over month.

Meclonazepam Detection by State Following Re-Emergence (June 2026-September 2026)

State Detection by Color
States in Orange: Tested and Detected
States in Green: Tested and Not Detected
States in Gray: Not Tested

Meclonazepam Detections Following Re-Emergence (June 2026-September 2026)

Meclonazepam Class/Drug
Co-Positivity

*Top Ten Drug Classes Detected in Samples where class was co-ordered in at least 70% of Samples.
Note: Not all specimens were tested for the same classes.

About Meclonazepam

  • Meclonazepam is an emerging designer benzodiazepine that has been identified in the illicit drug supply and marketed online as a novel psychoactive substance. Structurally related to clonazepam, it is one of many non-medical benzodiazepine analogs that continue to appear in the evolving drug landscape.1-3
  • Designer benzodiazepines are frequently encountered in polysubstance use and may increase overdose risk when combined with opioids or other central nervous system depressants. Their sedative effects can contribute to respiratory depression, impaired cognition, and other serious adverse outcomes.2
  • The continued emergence of novel benzodiazepine analogs presents ongoing challenges for toxicology testing, clinical interpretation, and public health surveillance. As new compounds enter the market, laboratories must continually adapt testing strategies to detect and monitor these substances.2,3
References
1.United Nations Office on Drugs and Crime (UNODC). Meclonazepam Substance Details. UNODC Early Warning Advisory on New Psychoactive Substances.Published 2022 Apr 1. doi:10.15585/mmwr.mm7113a3
2. Brunetti P, Giorgetti R, Tagliabracci A, Huestis MA, Busardò FP. Designer Benzodiazepines: A Review of Toxicology and Public Health Risks. Pharmaceuticals. 2021;14(6):560.doi:10.3390/ph14060560.https://www.tandfonline.com/doi/epdf/10.1080/15563650.2025.2594070?needAccess=true
3. National Institute on Drug Abuse (NIDA). Emerging Drug Trends. National Institutes of Health; updated June 17, 2024.

Sign up for the Aegis Newsletter

      Close